Skye Bioscience Unveils Presentation Highlighting Nimacimab’s Potential to Enhance Obesity Treatments

Reuters11-24

Skye Bioscience Unveils Presentation Highlighting Nimacimab's Potential to Enhance Obesity Treatments

Skye Bioscience Inc. has provided an update on the development of nimacimab, a novel therapeutic candidate for obesity and metabolic diseases. According to the presentation, nimacimab is positioned as a complementary treatment to existing GLP-1 therapies, offering approximately 3% additional weight loss when used in combination with semaglutide over 26 weeks. The data also indicate a lower rate of post-treatment weight rebound and a favorable body composition profile compared to GLP-1 monotherapy. The company highlights nimacimab's differentiated peripheral CB1 mechanism, which does not increase gastrointestinal or neuropsychiatric adverse events in combination regimens. Skye Bioscience reports a clear pharmacokinetic and exposure-response profile from Phase 2a studies and is planning further evaluation at higher doses. Nimacimab is presented as suitable for both patients who do not respond to or tolerate GLP-1 therapies and for those seeking enhanced weight loss outcomes. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585461547?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585461547","market":"fut","top_or_hot":-1,"title":"Skye Bioscience Unveils Presentation Highlighting Nimacimab’s Potential to Enhance Obesity Treatments","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Skye Bioscience Unveils Presentation Highlighting Nimacimab's Potential to Enhance Obesity Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SKYE\">Skye Bioscience Inc.</a> has provided an update on the development of nimacimab, a novel therapeutic candidate for obesity and metabolic diseases. According to the presentation, nimacimab is positioned as a complementary treatment to existing GLP-1 therapies, offering approximately 3% additional weight loss when used in combination with semaglutide over 26 weeks. The data also indicate a lower rate of post-treatment weight rebound and a favorable body composition profile compared to GLP-1 monotherapy. The company highlights nimacimab's differentiated peripheral CB1 mechanism, which does not increase gastrointestinal or neuropsychiatric adverse events in combination regimens. Skye Bioscience reports a clear pharmacokinetic and exposure-response profile from Phase 2a studies and is planning further evaluation at higher doses. Nimacimab is presented as suitable for both patients who do not respond to or tolerate GLP-1 therapies and for those seeking enhanced weight loss outcomes. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Skye Bioscience Unveils Presentation Highlighting Nimacimab’s Potential to Enhance Obesity Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSkye Bioscience Unveils Presentation Highlighting Nimacimab’s Potential to Enhance Obesity Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-24 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Skye Bioscience Unveils Presentation Highlighting Nimacimab's Potential to Enhance Obesity Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SKYE\">Skye Bioscience Inc.</a> has provided an update on the development of nimacimab, a novel therapeutic candidate for obesity and metabolic diseases. According to the presentation, nimacimab is positioned as a complementary treatment to existing GLP-1 therapies, offering approximately 3% additional weight loss when used in combination with semaglutide over 26 weeks. The data also indicate a lower rate of post-treatment weight rebound and a favorable body composition profile compared to GLP-1 monotherapy. The company highlights nimacimab's differentiated peripheral CB1 mechanism, which does not increase gastrointestinal or neuropsychiatric adverse events in combination regimens. Skye Bioscience reports a clear pharmacokinetic and exposure-response profile from Phase 2a studies and is planning further evaluation at higher doses. Nimacimab is presented as suitable for both patients who do not respond to or tolerate GLP-1 therapies and for those seeking enhanced weight loss outcomes. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL8JPPYQ:1","article_id":"2585461547","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585461547","pubTimestamp":1763985851,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Skye Bioscience Inc. has provided an update on the development of nimacimab, a novel therapeutic candidate for obesity and metabolic diseases. According to the presentation, nimacimab is positioned as a complementary treatment to existing GLP-1 therapies, offering approximately 3% additional weight loss when used in combination with semaglutide over 26 weeks. The data also indicate a lower rate of post-treatment weight rebound and a favorable body composition profile compared to GLP-1 monotherapy. The company highlights nimacimab's differentiated peripheral CB1 mechanism, which does not increase gastrointestinal or neuropsychiatric adverse events in combination regimens. Skye Bioscience reports a clear pharmacokinetic and exposure-response profile from Phase 2a studies and is planning further evaluation at higher doses. Nimacimab is presented as suitable for both patients who do not respond to or tolerate GLP-1 therapies and for those seeking enhanced weight loss outcomes. You can acce","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SKYE":"Skye Bioscience Inc."},"translate_title":"Skye Bioscience发布演示文稿，强调Nimacimab增强肥胖治疗的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SKYE":0.9},"content_text":"Skye Bioscience Unveils Presentation Highlighting Nimacimab's Potential to Enhance Obesity Treatments\n    \n\nSkye Bioscience Inc. has provided an update on the development of nimacimab, a novel therapeutic candidate for obesity and metabolic diseases. According to the presentation, nimacimab is positioned as a complementary treatment to existing GLP-1 therapies, offering approximately 3% additional weight loss when used in combination with semaglutide over 26 weeks. The data also indicate a lower rate of post-treatment weight rebound and a favorable body composition profile compared to GLP-1 monotherapy. The company highlights nimacimab's differentiated peripheral CB1 mechanism, which does not increase gastrointestinal or neuropsychiatric adverse events in combination regimens. Skye Bioscience reports a clear pharmacokinetic and exposure-response profile from Phase 2a studies and is planning further evaluation at higher doses. Nimacimab is presented as suitable for both patients who do not respond to or tolerate GLP-1 therapies and for those seeking enhanced weight loss outcomes. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585461547","isCrawlerRequest":true}